Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Antibiotics Dilemma

Executive Summary

The new antibiotics start-ups make perfect sense: big marketplace need; straightforward clinical development. But the biotech world has changed so radically that even sensible start-ups face daunting odds. The lack IPO or acquisition possibilities force companies to rely almost entirely on partnerships. We examine three companies' strategies: Applied Microbiology is pursuing the most radical near-term strategy of all biotechs in order to cover the downside risk of its antibiotic research. Microcide cuts risk by trying to come up with as many research targets as possible, adding a mid-term focus by trying to modify current compounds into valuable niche drugs. And Cubist is racing to create a solid proprietary position around its core program, a single group of targets, hoping to offer partners a series of opportunities.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV000094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel